For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Attruby represents a genuine breakthrough . These groundbreaking therapies https://attr-cm502683.webbuzzfeed.com/42476276/major-attr-cm-breakthrough-tafamidis-and-tafamidis-meglumine-give-promise